Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB5 | P28074 | 3/20 | 0.44 |
| ▸ | PSMB1 | P20618 | 2/20 | 0.44 |
| ▸ | PSMB2 | P49721 | 2/20 | 0.44 |
| ▸ | REN | P00797 | 9/20 | 0.43 |
| ▸ | SIRT1 | Q96EB6 | 2/20 | 0.42 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.42 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.42 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.42 |
| ▸ | PSMB9 | P28065 | 1/20 | 0.42 |
| ▸ | KLK7 | P49862 | 1/20 | 0.41 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21097236 | 0.92 | SIRT1 (0.40) | PSMB5PSMB1PSMB2SIRT1SIRT2 | |
| SCHEMBL25863358 | 0.90 | SIRT5 (0.52) | PSMB5PSMB1PSMB2RENSIRT1 | |
| SCHEMBL21097237 | 0.82 | PSMB8 (0.49) | PSMB5SIRT1SIRT2SIRT5PSMB8 | |
| SCHEMBL21097238 | 0.81 | SIRT5 (0.49) | PSMB5PSMB2SIRT1SIRT2SIRT5 | |
| SCHEMBL18774075 | 0.81 | SIRT2 (0.50) | PSMB5SIRT1SIRT2SIRT5PSMB8 | |
| SCHEMBL25863218 | 0.80 | MMP3 (0.34) | RENSIRT1SIRT2SIRT5 | |
| SCHEMBL18752309 | 0.80 | SIRT2 (0.49) | PSMB5SIRT1SIRT2SIRT5PSMB8 | |
| SCHEMBL18782520 | 0.76 | KLK7 (0.53) | SIRT1SIRT2KLK7KLK5 | |
| SCHEMBL18770780 | 0.76 | KLK7 (0.53) | SIRT1SIRT2KLK7KLK5 | |
| SCHEMBL18770781 | 0.76 | KLK7 (0.53) | SIRT1SIRT2KLK7KLK5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11696956-B2 | Bicyclic peptide ligands specific for EphA2 | BICYCLETX LIMITED (GB) | 2023-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11696956-B2 | Bicyclic peptide ligands specific for EphA2 | EPHA2, EPHB2, ERBB2 | PSMB5 3617/4885PSMB1 4280/4885PSMB2 3834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.